(301) 657-9883
CDC Reports That STD Cases Continued to Rise During First Year of COVID-19 Pandemic

CDC Reports That STD Cases Continued to Rise During First Year of COVID-19 Pandemic

Sexually transmitted disease (STD) infections in the United States continued to rise in 2020, with cases of gonorrhea and syphilis in particular surpassing their 2019 levels. Apparent declines in total reported STDs early in the year were likely driven by the effects of the COVID-19 pandemic, which disrupted STD surveillance and treatment efforts across the country and continues to impact our healthcare system.

According to a report released this month by the Centers for Disease Control and Prevention (CDC), 2.4 million cases of STDs were reported in the U.S. in 2020. Congenital syphilis saw the most dramatic increase, with cases rising by almost 15 percent since 2019 and by 235 percent since 2016, while gonorrhea and primary and secondary syphilis cases increased by 10 percent and 7 percent from 2019, respectively. The report also found that some racial and ethnic minority groups, gay and bisexual men, and young people continue to experience higher rates of STDs.

Reported cases of chlamydia fell by 13 percent, however, while overall STD cases fell dramatically in the early months of 2020. According to the report, these apparent declines were likely driven not by an actual reduction in new infections but rather by the COVID-19 pandemic, which led to reductions in STD screenings by providers, caused resource and supply shortages, and led many patients to delay or avoid making healthcare visits.

“There were moments in 2020 when it felt like the world was standing still,” according to Dr. Jonathan Mermin, Director of CDC’s National Center for HIV, Viral Hepatitis, STD, and TB Prevention. “But STDs weren’t. The unrelenting momentum of the STD epidemic continued even as STD prevention services were disrupted.”

To read the full CDC report, visit https://www.cdc.gov/std/statistics/2020/default.htm.

CDC Provides Guidance on Talking With Parents About COVID-19 Vaccination

As the COVID-19 pandemic continues to rage, the Centers for Disease Control and Prevention (CDC) urges everyone ages 5 and older to get vaccinated as soon as possible. More than 543 million doses of COVID-19 vaccine had been given in the United States through February 7, 2022, according to CDC.

Despite the safety of the vaccines, misinformation remains a problem nationwide. CDC provides recommendations for providers on how to answer questions from parents and caregivers about COVID-19 vaccines. Providers remain the most trusted source of information about vaccines.

Opioid Use Disorder and the Medicare/Medicaid Population

Opioid Use Disorder and the Medicare/Medicaid Population

BETHESDA, MD – The United States has long been engulfed in an opioid epidemic that stemmed from increased prescribing of opioids in the 1990s and is characterized today by use of synthetic opioids, like fentanyl, as well as illicit opioids such as heroin.[1] By 2017, there were 58 opioid prescriptions written for every 100 Americans.[2] This rise in opioid use has led to an increased prevalence of Opioid Use Disorder (OUD) in a variety of populations.

OUD—which may involve the misuse of prescribed opioid medications, diverted opioid medications, or illicitly obtained heroin—is typically a chronic, relapsing illness associated with significant rates of morbidity and mortality.[3] The Diagnostic and Statistical Manual of Mental Disorders, 5th Edition, describes OUD as a “pattern of opioid use leading to problems or distress,” with at least two of the following occurring within a 12-month period:[4]

  1. Taking larger amounts or taking drugs over a longer period than intended.
  2. Persistent desire or unsuccessful effort to cut down or control opioid use.
  3. Spending a great deal of time obtaining or using the opioid or recovering from its effects.
  4. Craving, or a strong desire or urge to use opioids.
  5. Problems fulfilling obligations at work, school, or home.
  6. Continued opioid use despite having recurring social or interpersonal problems.
  7. Giving up or reducing activities because of opioid use.
  8. Using opioids in physically hazardous situations.
  9. Continued opioid use despite ongoing physical or psychological problems likely to have been caused or worsened by opioids.
  10. Increased tolerance (i.e., need for increased amounts, or diminished effect with continued use of the same amount).
  11. Experiencing withdrawal (opioid withdrawal syndrome) or taking opioids (or a closely related substance) to relieve or avoid withdrawal symptoms.

Although OUD is similar to other substance use disorders, there are many unique features, including risk of physical dependence in as little as 4 to 8 weeks and severe symptoms such as chills, cramps, vomiting, and insomnia during withdrawal.[3] Despite its unique features, the factors contributing to OUD are very general and can include ease of access, environmental and genetic factors, social support system, addictivity of the drug, and early use.

Looking at the rate of opioid prescribing among Medicare and Medicaid beneficiaries can help us gain an understanding of the development of OUD in America. In 2018, the Centers for Medicare & Medicaid Services (CMS) analyzed the prevalence of OUD among beneficiaries and reported that 6 out of every 1,000 Medicare beneficiaries and 8.7 of every 1,000 Medicaid beneficiaries suffer from OUD.[5] Using data from 2006 to 2015, another CMS study found that 23.5 percent of dual-eligible beneficiaries in 2015 had a substance use disorder.[6] For the Medicaid-only population, there were 31 million opioid claims in 2017, and opioid prescriptions represented 4.57 percent of all Medicaid prescription claims.[7] One year earlier, in 2016, 14.4 million of the 43.6 million Medicare-only beneficiaries enrolled in Part D received opioids.[8]

The national data for OUD and opioid prescriptions is presented here to provide the foundation for a larger discussion around OUD in the United States. Over the course of this series of newsletters, we will dive into topics such as OUD treatment options, how COVID-19 is impacting treatment centers across the country, and much more.

[1] Centers for Disease Control and Prevention (CDC). (2020). Opioid overdose: Understanding the epidemic. Retrieved from https://www.cdc.gov/drugoverdose/epidemic/index.html.

[2] CDC. (2020). Opioid overdose: Prescribing practices. Retrieved from https://www.cdc.gov/drugoverdose/data/prescribing/ prescribing-practices.html.

[3] Strain, E. (2020). Opioid use disorder: Epidemiology, pharmacology, clinical manifestations, course, screening, assessment, and diagnosis. UpToDate. Retrieved from https://www.uptodate.com/contents/opioid-use-disorder-epidemiology-pharmacology-clinical-manifestations-course-screening-assessment-and-diagnosis.

[4] American Psychiatric Association. (2018). Opioid use disorder. Retrieved from https://www.psychiatry.org/patients-families/addiction/opioid-use-disorder/opioid-use-disorder.

[5] CMS. (2018, June 11). CMS opioids roadmap. CMS.gov Blog. Retrieved from https://www.cms.gov/blog/cms-opioids-roadmap.

[6] Anderson, K. K., Hendrick, F., & McClair, V. (2018, October). Data analysis brief: National trends in high-dose chronic opioid utilization among dually eligible and Medicare-only beneficiaries (2006-2015). Retrieved from https://www.cms.gov/Medicare-Medicaid-Coordination/Medicare-and-Medicaid-Coordination/Medicare-Medicaid-Coordination-Office/DataStatisticalResources/Downloads/OpioidsDataBrief_2006-2015_10242018.pdf

[7] CMS. (2019). Medicaid State Opioid Prescribing Mapping Tool. Retrieved from https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/Medicare-Provider-Charge-Data/OpioidMap

[8] Office of Inspector General. (2017, July). Opioids in Medicare Part D: Concerns about extreme use and questionable prescribing [OEI-02-17-00250]. U.S. Department of Health & Human Services. Retrieved from https://oig.hhs.gov/oei/reports/oei-02-17-00250.pdf.

About Econometrica:

Founded in 1998, Econometrica is a research and management organization in Bethesda, MD, established to provide public- and private-sector clients with customized program support services. Econometrica works with multiple agencies to provide high-quality, cost-effective analyses, modeling, and economic evaluations. The company consistently receives exceptional scores from its clients and believes in three principles: technical capabilities, happy customers, and business development.

Opioid Use Disorder (OUD)—which may involve the misuse of prescribed opioid medications, diverted opioid medications, or illicitly obtained heroin—is typically a chronic, relapsing illness associated with significant rates of morbidity and mortality.

Press Contact

Jonathan Fusfield

Econometrica Maintains Continued Operations During Coronavirus Pandemic

Econometrica Maintains Continued Operations During Coronavirus Pandemic

BETHESDA, MD – On March 13, President Trump declared a national emergency in response to the outbreak of coronavirus (COVID-19) nationwide. Econometrica, Inc., continues to monitor developments related to the coronavirus pandemic to ensure the safety of our staff, their families, and communities. We also are taking steps toward meeting our commitments to clients and partners and continue to provide the high-quality and timely services expected from Econometrica.

The following summarizes steps we have taken to date:

  • Econometrica has mandated that all employees work full time from home for the foreseeable future. We are complying with guidelines from the Centers for Disease Control and Prevention (CDC) to halt gatherings of more than 50 people and to encourage social distancing.
  • Employees working remotely have full access, using secure configurations, to Econometrica’s network resources, applications, and support, including communication tools to support telework. No project work will be interrupted by this move to a remote setup.
  • Project teams in our Health, Housing and Community Development, General Services, Capital Markets, and Data Analytics groups are moving toward scheduling all meetings virtually and limiting travel. All business travel is temporarily suspended during this time.
  • Staff members who work onsite at our clients’ offices continue to report to their respective agencies unless directed otherwise. We have been in contact with each client to develop contingency plans to address remote work should access to the client site is limited or an employee shows symptoms of COVID-19.
  • We have regularly communicated prevention strategies and tips from CDC and the American Red Cross for keeping homes and workplaces safe. Everyone has been advised to call their doctors and follow CDC recommendations for self-quarantine should they show any symptoms related to COVID-19.

Coronavirus infections increase at an exponential rate, with symptoms including fever, cough, and shortness of breath. Social distancing seems to be effective in reducing the spread, and Econometrica wants its employees to feel safe and remain healthy. As this outbreak unfolds, Econometrica will continue to provide its high-quality services with no reduction in availability or commitment.

About Econometrica:

Founded in 1998, Econometrica is a research and management organization in Bethesda, MD, established to provide public- and private-sector clients with customized program support services. Econometrica works with multiple agencies to provide high-quality, cost-effective analyses, modeling, and economic evaluations. The company consistently receives exceptional scores from its clients and believes in three principles: technical capabilities, happy customers, and business development.

Coronavirus infections increase at an exponential rate, with symptoms including fever, cough, and shortness of breath. Social distancing seems to be effective in reducing the spread, and Econometrica wants its employees to feel safe and remain healthy.

Press Contact

Jonathan Fusfield

View Related Posts

New HUD Reports Explore Recent AHS Data

New HUD Reports Explore Recent AHS Data

March 25, 2022

The U.S. Department of Housing and Urban Development (HUD) released two new reports about the examining data provided by the American Housing Survey (AHS).